Walder Wyss has advised SixPeaks Bio AG and its shareholders (including Versant Ventures). Lenz & Staehelin has advised AstraZeneca. AstraZeneca has completed the acquisition of Swiss...
AstraZeneca Acquires Swiss Biotech Firm SixPeaks Bio in USD 300 Million Deal
Helicore Biopharma’s $65 Million Series A Financing Round
Wilson Sonsini Goodrich & Rosati advised Versant Ventures and OrbiMed on the transaction. Helicore Biopharma, a biopharmaceutical company focused on the discovery and development of first-in-class...
Pierre Fabre Laboratories’ Acquisition of Vertical Bio AG
Walder Wyss advised Versant Ventures on this transaction. ierre Fabre Laboratories, the French pharmaceutical and dermo-cosmetic company, announced the acquisition of Vertical Bio AG, a developer...
Nexo Therapeutics’ $60 Million Series A Financing Round
Wilson Sonsini Goodrich & Rosati advised Versant Ventures and New Enterprise Associates on the deal. Nexo Therapeutics (Nexo) announced it has emerged from stealth with $60 million...
Vector BioPharma’s USD 30 Million Series A Funding Round
Walder Wyss advised Versant Ventures on the deal. Versant Ventures announced the debut of Vector BioPharma, a biopharmaceutical company developing a precision gene delivery platform that...
Cimeio Therapeutics’ $50 Million Series A Financing Round
Walder Wyss advised Versant Ventures on the deal. VISCHER advised Cimeo Therapeutics. Versant Ventures announced the debut of Cimeio Therapeutics, a biotechnology company developing a novel...
858 Therapeutics’ $60 Million Series A Financing
Wilson Sonsini Goodrich & Rosati advised New Enterprise Associates (NEA) and Versant Ventures on the deal. 858 Therapeutics announced the completion of a $60 million Series...
Stablix Therapeutics’ $63 Million Series A Financing
Wilson Sonsini Goodrich & Rosati advised Versant Ventures and NEA on the deal. Stablix Therapeutics announced a $63 million Series A financing. The funding round was...